enzalutamide articles & resources on Made-in-China.com

Astellas Announced The Availability of Xtandi a New Treatment for Advanced Prostate Cancer

Jul 12, 2013

Astellas Pharma has announced the availability of Xtandi (enzalutamide), a new treatment for advanced prostate cancer in patients who have failed on first-line hormonal treatments and docetaxel chemotherapy, in the UK. Administered ...

Tags: Astellas, Cancer Medication

Astellas Pharma and Medivation Have Announced The Health Canada Approval of Xtandi

Jun 4, 2013

Astellas Pharma and Medivation have announced the Health Canada approval of Xtandi (enzalutamide) capsules to treat metastatic castration-resistant prostate cancer. The oral, once-daily androgen receptor inhibitor is indicated for ...

Tags: Astellas Pharma, Medicine

Astellas Pharma and Medivation Have Announced The Submission of Application

May 27, 2013

Astellas Pharma and Medivation have announced the submission of application for marketing approval of enzalutamide in Japan for the treatment of prostate cancer. The application was filed by Astellas with the Ministry of Health, Labour ...

Tags: Astellas, Marketing Application

Medivation and Astellas Pharma Have Announced FDA Approval

Dec 14, 2012

Medivation and Astellas Pharma have announced FDA approval for Xtandi (enzalutamide) capsules to treat metastatic castration-resistant prostate cancer in patients with previously received docetaxel. Medivation and Astellas expect to make ...

Tags: Medivation, Astellas, FDA

Xtandi Is Being Distributed Through a Network of Specialty Pharmacies and Distributors

Nov 30, 2012

Medivation and Astellas Pharma have launched Xtandi (enzalutamide) capsules for patients with metastatic castration-resistant prostate cancer who have previously received docetaxel. Xtandi, an oral, once-daily androgen receptor inhibitor ...

Tags: Medivation Pharma, Astellas Pharma, Xtandi capsules

MAA for Enzalutamide is Submitted to EMA by Astellas

Jun 27, 2012

Astellas Pharma and Medivation have announced the submission of marketing authorization application (MAA) to the European Medicines Agency (EMA) for enzalutamide to treat metastatic castration-resistant prostate cancer in men who have ...

Tags: enzalutamide, metastatic castration-resistant prostate cancer

Medivation and Astellas Pharma Announced The Submission of NDA

May 23, 2012

Medivation and Astellas Pharma have announced the submission of new drug application (NDA) for enzalutamide (formerly MDV3100) to the FDA. The enzalutamide has been studied in patients with castration-resistant prostate cancer who ...

Tags: enzalutamide, new drug application, pharmaceutical product